VCG
EGRX

Vantage Consulting Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Vantage Consulting Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-485
Closed -$23K – 1668
2020
Q4 		$23K Buy
+485
New +$22.7K ﹤0.01% 825

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vantage Consulting Group's EGRX Position: Q1 2021 in Review

Vantage Consulting Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 485 shares — an estimated $23K sold.

Vantage Consulting Group first reported a position in EGRX in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

  • Vantage Consulting Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 485 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $23K.
  • Vantage Consulting Group first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Eagle Pharmaceuticals, Inc. position peaked at $23K in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.